Arabinose

Other Names

(2R,3S,4S)-2,3,4,5-tetrahydroxypentanal(2R,3S,4S)-2,3,4,5-tetrahydroxyvaleraldehyde(2S,3R,4R)-2,3,4,5-tetrahydroxypentanal(2S,3R,4R)-2,3,4,5-tetrahydroxyvaleraldehydealdehydo-D-arabino-pentosealdehydo-D-arabinosealdehydo-L-arabinosearabinopyranoseArabinose, D- (8CI)Arabinose, D- (9CI)D-AraD-arabino-pentoseD-ArabinopyranoseD-ArabinoseDL-ArabinoseGum sugarL(+)-PectinoseL-AraL-arabino-pentoseL-ArabinopyranoseL-ArabinoseL-GalactohexoseL-pentosePectin sugarPectinoseα-D-Arabinopyranoseα-L-Arabinopyranoseβ-D-Arabinopyranoseβ-L-Arabinopyranose

Synopsis

L-Arabinose: A Comprehensive Reference

1. Identity and Chemical Profile

Arabinose is a crystalline pentose sugar with the chemical formula C₅H₁₀O₅, derived from plant polysaccharides such as gums. It belongs to the class of aldopentoses — five-carbon monosaccharides bearing an aldehyde group — and exists in two enantiomeric forms: L-arabinose and D-arabinose. The biologically and commercially relevant form is L-arabinose (also written l-arabinose or L-(+)-arabinose). Its IUPAC name is (2S,3R,4S)-2,3,4,5-tetrahydroxypentanal, and it is registered in PubChem under CID 439195.

L-arabinose is a rare sugar that exists in the L-form and is the second most widespread pentose sugar after D-xylose in nature. L-arabinose is a plant-specific sugar accounting for 5–10% of cell wall saccharides in Arabidopsis thaliana and rice (Oryza sativa). It occurs in pectic arabinan, rhamnogalacturonan II, arabinoxylan, arabinogalactan-protein (AGP), and extensin in the cell walls, as well as in glycosylated signalling peptides and small glycoconjugates.

L-arabinose has a very similar taste to sucrose, but with half the sweetness of sucrose. L-arabinose is a non-caloric sugar, which could affect glucose and lipid metabolism and suppress obesity. L-arabinose is a monosaccharide and aldopentose found naturally in certain plant cell walls, including many grains and plant gums. It has half the sweetness of sucrose and has been shown in animals to be less metabolizable compared with glucose.

Common Names and Synonyms

L-arabinose (preferred common name)
L-(+)-arabinose
Pectinose (historical)
Gum sugar (historical, reflecting its early isolation from plant gums)

2. Natural Sources and Distribution

L-arabinose is widely distributed in plant materials, particularly as a component of hemicellulose and pectin. It is primarily found in the side chains of hemicellulose and pectin biopolymers as arabinogalactan-protein complexes and is commonly found in lignocellulosic biomass-based feedstocks such as corn fiber, wheat bran, sugar beet pulp, brewer's spent grains, and lime peels.

In nature, L-arabinose often exists as the hemicelluloses L-araban and L-araban-D-galactan, which are found in mesquite gum, cherry gum, peach gum, rye and wheat bran, beet pulp, and in the wood of coniferous trees. In some of these sources, the content of these hemicelluloses is substantial. For example, 20–30% of the pectic substance in sugar beet is araban, and the wood of the genus Larix may contain 25% L-araban-D-galactan.

In nature, L-arabinose exists in fruit purées, hemicellulose, and pectate in the form of polysaccharide araban, L-araboxylan, and L-arabinogalactan.

3. Production and Commercial Preparations

L-arabinose can be industrially produced from arabinan-, arabinoxylan-, or arabinogalactan-containing plant biopolymers, including wood materials, vegetable and fruit processing by-products, or agro-industrial residues such as corncob and sugar beet pulp. The α-glycosidic linkages of arabinose hydrolyse more readily compared to β-glycosidic ones, which facilitates arabinose release from hemicellulose-containing biomass, because arabinose is primarily found in the furanose form, connected by α-glycosidic bonds as side chain to the hemicellulose backbone.

An early study described a method for the preparation of crystalline L-arabinose from arabinoxylan in corn fiber by enzymatic hydrolysis, followed by selective fermentation by yeast. This method uses enzymes produced by fungi (e.g., enzymes extracted from Penicillium funiculosum) to enzymatically hydrolyze arabinoxylan to produce L-arabinose and D-xylose.

L-arabinose can be obtained by hydrolysis of beet pulp, which gives a mixture of L-arabinose, D-galactose, and sucrose. If stronger hydrolysis conditions are used, the product mixture will also contain glucose and fructose.

Commercially, L-arabinose is available in several forms:

Crystalline powder: the predominant supplement and food-grade form, produced by acid or enzymatic hydrolysis of plant hemicelluloses followed by chromatographic purification.
Functional food additive: incorporated into beverages, baked goods, confectioneries, and dairy products, often at defined weight percentages relative to sucrose content.
Blended sugar products: combined with sucrose or other sweeteners to reduce the glycaemic impact of the resulting product.

A GRAS notice filed with the U.S. FDA described L-arabinose for use as a sweetener in baked goods and baking mixes, beverages, bars (energy, snack, and sports nutrition), cereal-based products, confectioneries and frostings, chewing gum, condiments, dairy products, desserts, fruit and water ices, spreads, snack foods, and sweet sauces and syrup, at up to 15% by weight.

4. Regulatory Status

L-arabinose was approved as Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration in 2018. L-arabinose has also been approved as a health food supplement by the Japanese Ministry of Health. Its listing in the FDA's food substances database (GRAS Notice GRN 000782) confirms its regulatory standing as a food ingredient and sweetener in the United States.

5. Traditional and Historical Use

L-arabinose as an isolated, purified compound has no documented history in traditional herbal medicine. It was first chemically characterised and named in the mid-nineteenth century, following the identification of arabans — arabinose-containing polysaccharides — in gum arabic (Acacia senegal), from which the name "arabinose" derives. The word references Arabia, reflecting the geographic origin of the gum arabic trade routes through which the parent polysaccharide was historically known to European chemists.

Plant gums rich in arabinan polysaccharides — notably gum arabic and other exudate gums — have been used for millennia across Middle Eastern, North African, and South Asian cultures as food-thickening, adhesive, and medicinal agents. However, their use was for the crude gum polysaccharide preparations, not for free L-arabinose. The isolation of arabinose as a discrete monosaccharide by acid hydrolysis of araban-containing gums is a product of nineteenth-century analytical chemistry, and therapeutic or nutritional application of the purified sugar is an entirely modern phenomenon, arising primarily from Japanese food science research in the 1990s and early 2000s, which identified its selective inhibitory effect on the intestinal enzyme sucrase.

6. Key Constituents and Active Compounds

Because L-arabinose is itself a single monosaccharide entity, it does not contain constituent compounds in the way a complex botanical extract would. Its biological activities arise from its own molecular structure and from the way mammalian and microbial metabolism interacts with that structure.

Structural Features Relevant to Activity

Arabinose is primarily found in the furanose form, connected by α-glycosidic bonds as a side chain to the hemicellulose backbone. In aqueous solution at physiological conditions, L-arabinose equilibrates between the open-chain aldehyde form and the closed furanose and pyranose ring forms. The molecular structure of L-arabinose contains an aldehyde group, which makes it a reducing monosaccharide.

Arabinitol (Arabinitol / Arabitol)

Using L-arabinose as a raw material, the rare sugar alcohol arabinitol can be produced through a hydrogenation synthesis reaction, which can also be used in microbial fermentation and genetic improvement experiments. Arabinitol appears in urine and plasma as a metabolic marker and can be measured to reflect arabinoside ingestion, though it is a metabolic derivative rather than an active ingredient per se.

7. Established Mechanisms of Action

7.1 Uncompetitive Inhibition of Intestinal Sucrase

The most thoroughly characterised and scientifically established mechanism of L-arabinose is its selective inhibition of sucrase-isomaltase (also known as intestinal sucrase), the brush-border enzyme responsible for hydrolysing sucrose into glucose and fructose before absorption.

Kinetic studies of sucrase inhibition have demonstrated that this was induced by L-arabinose in an uncompetitive manner, unlike acarbose which acts in a competitive manner. Competitive inhibition is defined as binding of an inhibitor to the catalytic site of the enzyme, competing with the primary substrate. Uncompetitive inhibition is defined as one in which an inhibitor binds only to an enzyme-substrate complex and inhibits its activity.

L-arabinose is a natural pentose with a sweet taste, and in animal studies it suppressed the increase in blood glucose at a low dose after sucrose ingestion (ED₅₀, 35 mg/kg) but showed no suppression of the increase in blood glucose after starch loading in mice. This selectivity for sucrase — with little or no inhibitory activity against other disaccharidases such as maltase at the doses studied — is an important feature distinguishing L-arabinose from broad-spectrum α-glucosidase inhibitors like acarbose.

Studies investigating the effects of L-arabinose on intestinal α-glucosidase activity in vitro and on postprandial glycaemic responses in vivo revealed L-arabinose's uncompetitive inhibition of sucrase, followed by a dose-dependent suppression of blood glucose. These studies also suggested that inhibition of blood glucose was achieved by specifically targeting sucrase without affecting other intestinal enzymes.

Enzyme kinetic analysis showed that at increasing concentrations of L-arabinose inhibitor (0.84, 1.4, and 2.8 mmol/L), both V_max and K_m decreased, and the addition of 0.84, 1.4, and 2.8 mmol/L L-arabinose/L resulted in 25%, 29%, and 38% inhibition of sucrase activity, respectively, at V_max.

7.2 Delayed Sucrose Digestion and Glucose Absorption

Recent research has further demonstrated that L-arabinose acts as a non-competitive inhibitor, delaying the breakdown of sucrose and thus slowing the absorption of glucose and fructose, which helps to control blood glucose levels. By delaying sucrose cleavage at the brush border, L-arabinose effectively slows the delivery of glucose and fructose into portal circulation.

7.3 Effects on Incretin Hormones

Beyond glycaemia, L-arabinose has been shown to modulate the secretion of incretin hormones. In human studies, supplementation with 4% L-arabinose produced an 11% lower glucose peak, a 33% lower and delayed insulin peak, a 23% reduction in the incremental area under the curve (iAUC) for insulin, a 23% lower and delayed C-peptide peak, a 9% reduction in the iAUC for C-peptide, a 53% increase in the iAUC for glucagon-like peptide-1 (GLP-1), and a 28% reduction in the iAUC for glucose-dependent insulinotropic polypeptide.

7.4 Prebiotic and Gut Microbiota Effects

L-arabinose (C₅H₁₀O₅), a plant-specific pentaose, is a potential prebiotic with multiple effects on alleviating lipid metabolic disorder, improving insulin resistance, and anti-inflammation. Because much of the ingested L-arabinose is not absorbed by the small intestine, it passes into the colon where it becomes available for fermentation by resident microbiota.

Results have revealed that L-arabinose significantly altered the gut microbiome structure, particularly elevating Bifidobacterium and short-chain fatty acids (SCFAs) both in vivo and in vitro. Subsequent in vitro experiments confirmed that L-arabinose increased the relative abundance of SCFA-producing bacteria and facilitated linoleic acid metabolism.

In one study using arabinogalactan, arabinose, and galactose, arabinose stimulated Gemmiger and Blautia — two genera associated with beneficial microbiome profiles.

7.5 Gut-Derived Hydrogen Production

L-arabinose, a naturally occurring plant pentose, has a promising future as a novel food ingredient with benefits in metabolic syndrome; yet the mechanisms remain to be further elucidated. Gut microbiota is recently recognized to play key roles in metabolic syndrome; molecular hydrogen, an emerging medical gas with reported benefits in metabolic syndrome, can be produced and utilized by gut microbes. Antibiotics treatment abolished L-arabinose-elicited hydrogen production independent of diet type, confirming gut microbes as the source of hydrogen. PCR of fecal 16S rDNA revealed modulation of relative abundances of hydrogen-producing and hydrogen-consuming gut microbes as well as probiotics by high-fat diet and L-arabinose.

8. Scientific Evidence by Area of Use

8.1 Postprandial Glycaemic and Insulinaemic Control

This is the most extensively studied application of L-arabinose in humans.

Krog-Mikkelsen et al. (2011) — American Journal of Clinical Nutrition

The objective was to investigate the dose-response effects of L-arabinose on intestinal sucrase activity in vitro and glucose tolerance, appetite, and energy intake in humans. In vitro, Caco-2 cells were cultured for 21 days, homogenized, and used as an enzyme preparation with sucrose as substrate in concentrations from 7 to 280 mmol/L with 0.84, 1.4, and 2.8 mmol L-arabinose/L as inhibitor. Released glucose was measured after 30 minutes. In the human studies, 15 healthy men participated in a randomized, double-blind, crossover study. Sucrose beverages (75 g in 300 mL) supplemented with 0%, 1.3%, 2.7%, and 4% by weight of L-arabinose were tested at breakfast.

In vitro, the addition of L-arabinose resulted in uncompetitive inhibition of sucrase activity. In the human studies, supplementation with 4% L-arabinose produced an 11% lower glucose peak, a 33% lower and delayed insulin peak, a 23% reduction in the incremental area under the curve (iAUC) for insulin, a 23% lower and delayed C-peptide peak, a 9% reduction in the iAUC for C-peptide, a 53% increase in the iAUC for glucagon-like peptide-1 (GLP-1), and a 28% reduction in the iAUC for glucose-dependent insulinotropic polypeptide. No effects on triacylglycerol, gastrointestinal symptoms, appetite ratings, or energy intake were observed. The study was funded by Nordic Sugar, Copenhagen, Denmark, which is a notable limitation regarding potential conflicts of interest.

Pol et al. (2022) — Nutrients (PMC8774789)

This study assessed the effect of fat or starch in a sugary drink on the efficacy of L-arabinose. Twenty-three healthy volunteers (12 female/11 male; aged 24 ± 3 years; BMI 23 ± 3 kg/m²) participated in a randomised cross-over trial with six drinks: control (50 g sucrose in water); fat (control + 22 g oil); starch (control + 50 g starch); and all three with and without the addition of 5 g L-arabinose. The addition of L-arabinose to the control drink lowered glucose and insulin peaks by 15% and 52%; for the fat drink by 8% and 45%; and for the starch drink by 7% and 29%. For all three drinks, adding L-arabinose increased GLP-1 responses and lowered glucose-dependent insulinotropic polypeptide. It was demonstrated that L-arabinose still lowers the postprandial glycaemic and insulinaemic response in healthy subjects, despite the presence of starch and fat, suggesting that L-arabinose maintains its functionality in the presence of starch and fat, two important compounds present in more complex foods and real-life foods.

Vreeken et al. (2022) — British Journal of Nutrition (PMC9381304)

In this double-blind, randomised crossover study, researchers assessed blood glucose kinetics following ingestion of a 200-mL drink containing 50 g of sucrose with 7.5 g of L-arabinose (L-ARA) or without L-arabinose (control) in twelve young, healthy participants (24 ± 1 years; BMI 22.2 ± 0.5 kg/m²). Plasma glucose kinetics were determined by a dual stable isotope methodology involving ingestion of (U-¹³C₆)-glucose-enriched sucrose and continuous intravenous infusion of (6,6-²H₂)-glucose. This isotope-dilution methodology provided direct mechanistic evidence of delayed sucrose-derived glucose absorption.

Halschou-Jensen et al. (2015) — British Journal of Nutrition [null result / mixed evidence]

In healthy human participants, supplementation of 20% L-arabinose relative to carbohydrate content to a single solid mixed meal did not alter glycaemic or insulinaemic responses. This negative result is important context: it suggests that the efficacy of L-arabinose may be substantially attenuated when incorporated into solid, complex, mixed-macronutrient food matrices as opposed to sucrose-rich aqueous beverages. L-arabinose lowers glycaemic and insulinaemic responses when added to simple water-based sugary liquids; however, the effect in more complex foods, including fat and starch, is inconsistent.

Haverkort et al. (2025) — Journal of Nutrition [individuals with impaired fasting glucose]

L-arabinose is a sucrase inhibitor that interferes with sucrose breakdown and has been shown to lower glycaemic and insulinaemic responses in healthy individuals; however, its effects in individuals with impaired fasting glucose (IFG) were unknown. Eighteen adults (4 females, 14 males; age 73 ± 4 y; BMI 27.5 ± 2.4 kg/m²) with IFG participated in a double-blind, randomized, cross-over trial. Participants received 10% w/w L-arabinose in a 550 mL sucrose drink or a sucrose-only drink (control). Blood glucose and insulin were measured before and ≤180 min post consumption. After this, participants consumed a 2-day controlled diet with sucrose-rich (9–10 en%) meals and snacks, preceded by a 15% w/w L-arabinose supplement or no L-arabinose (control). A single treatment of 10% w/w L-arabinose significantly reduced glucose peaks (−14%) and insulin peaks (−30%), with delays of 10 and 32 minutes, respectively. Continuous glucose monitoring also revealed significant reductions in variability compared with control: standard deviation (−25%), coefficient of variation (−24%), and mean amplitude of glycaemic excursions (−26%).

Overall Evidence Assessment — Glycaemic Control

With no caloric value, most of the studies examining consumption of L-arabinose in humans are acute postprandial studies, and they demonstrate a benefit on glycaemic control in healthy individuals. All acute trials examining the effect of L-arabinose in humans were conducted using a randomized controlled crossover design. The body of evidence is moderate in quality: multiple well-designed acute crossover trials confirm postprandial benefit when L-arabinose is co-ingested with sucrose-containing beverages; effects in solid mixed meals are less consistent; and long-term human intervention data remain sparse. There is a significant difference in study designs, mostly in terms of the investigated population (age, gender and health status), administered dose and duration (hours to months); there is an urgent need for additional, more well-designed clinical studies.

8.2 Metabolic Syndrome and Body Weight

Animal evidence (rat model, PMC4676841)

This study explored the effects of L-arabinose in rats with metabolic syndrome induced by a high-carbohydrate, high-fat (HCHF) diet. After establishing the rat model for metabolic syndrome, L-arabinose was administered by oral gavage for 6 weeks. The biochemical index and histological analysis were measured, and the expression levels of genes related to fatty acid metabolism were analyzed using real-time PCR. Following treatment with L-arabinose, metabolic syndrome rats had an obvious reduction in body weight, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglycerides, total cholesterol, serum insulin, TNF-α, and leptin. Further study showed that treatment with L-arabinose significantly increased the expression of mRNA for hepatic CPT-1α and PDK4, but the expression of mRNA for hepatic ACCα was reduced. This work suggests that L-arabinose could lower body weight, Lee's index, and visceral index and improve dyslipidaemia, insulin resistance, inflammation, and viscera function, indicating that it might be a promising candidate for therapies combating metabolic syndrome. This study is preclinical and cannot be directly extrapolated to humans.

Human evidence — metabolic syndrome (limited)

A human study determined the effects of consumption of L-arabinose on metabolic syndrome. All volunteers received L-arabinose by dissolving it in water. The volunteers did not change their diet habits and lifestyles during the whole experiment. The trial lasted for 6 months, and experimental indicators were assayed every two months, including weight, waist circumference, blood pressure, triglycerides, total cholesterol, HDL-C, LDL-C, fasting plasma glucose, serum uric acid, serum creatinine, blood urea nitrogen, ALT, and AST. Results showed that L-arabinose decreased waist circumference, total cholesterol, fasting glucose, serum uric acid, and ALT, and slightly increased HDL-C and slightly decreased diastolic blood pressure after 6 months. A tendency for decreased waist circumference, total cholesterol, fasting glucose, serum uric acid, and ALT after 2, 4 and 6 months of treatment with L-arabinose was observed. In addition, L-arabinose decreased total cholesterol, LDL-C, and body weight. No effects on serum creatinine, BUN, or AST were noted. This study's sample size, design details, and publication status limit the strength of conclusions that can be drawn.

Animal evidence — postprandial blood glucose and body weight

After 30 days' feeding in one study, the decrease of postprandial blood glucose level was observed in a group receiving 3% L-arabinose, and groups with 5–10% showed a significantly decreasing postprandial blood glucose level compared with control. The conclusion was that daily consumption of L-arabinose would inhibit the postprandial blood glucose level and reduce body weight. This again represents preclinical data and requires confirmation in rigorous human trials.

8.3 Gut Microbiota Modulation and Prebiotic Effects

Studies have shown that L-arabinose can precisely regulate key microbial communities in the colon and modulate the metabolic pathways of key metabolites, thereby relieving constipation. L-arabinose therefore has potential as a new food resource component for preventing functional constipation.

It was observed that there were changes in several dominant microbial populations, like Lactobacillus, Acidothermus, and Bacteroides, along with alterations in their metabolites, such as lithocholic acid, pantothenic acid, deoxycholic acid, and dodecanedioic acid. However, the relationship between these observed changes and the overall promotion of intestinal health in humans remains to be further explored and established.

One study examined the effects of L-arabinose on mouse intestinal microbiota and urinary isoflavonoids. Male mice were randomly divided into a group fed 0.05% daidzein–2.5% L-arabinose diet and a control group fed a 0.05% daidzein diet for 28 days. The amounts of daidzein detected in urine were significantly lower in the L-arabinose group. The ratio of equol/daidzein was significantly higher in the L-arabinose group. The composition of caecal flora differed between the groups. The occupation ratios of Prevotella and Lactobacillales were significantly lower in the L-arabinose group. This study suggests that dietary L-arabinose has the potential to affect the metabolism of equol from daidzein by altering the metabolic activity of intestinal microbiota. These are mouse data and their human relevance is uncertain.

Evidence grade: Prebiotic effects are supported by animal and in vitro studies, with limited human data. The mechanisms are plausible and consistent with the partial colonic fermentation of L-arabinose, but robust human clinical trials directly testing prebiotic endpoints are lacking.

8.4 Lipid Metabolism

Animal studies (see section 8.2) suggest L-arabinose may reduce serum triglycerides and total cholesterol in the context of a high-fat, high-carbohydrate dietary model. The human metabolic syndrome study referenced above reported reductions in total cholesterol and LDL-C, but the study's methodological limitations — including small sample size, absence of a placebo-controlled arm as described, and publication in a limited-access journal — prevent firm conclusions. No dedicated, large-scale human lipid trials have been identified in the peer-reviewed literature. This area remains preliminary.

8.5 Colitis and Gastrointestinal Inflammation

Research has demonstrated that L-arabinose acts as a non-competitive inhibitor, delaying the breakdown of sucrose and thus slowing the absorption of glucose and fructose, which helps to control blood glucose levels. This also benefits the attenuation of chronic gastrointestinal inflammatory conditions, as tested in a dextran sulfate-induced colitis animal model. These findings are from animal models only and have not been confirmed in human clinical trials.

8.6 Pharmaceutical Applications — Antiviral Drug Synthesis

L-arabinose can be used to synthesise antiviral drugs such as nucleoside analogues; for example, it is used as a raw material to synthesise 2-deoxy-2-fluoro-5-methyl-β-L-arabinose furanosouridine (L-FMAU). L-FMAU is a potent anti-hepatitis B virus (HBV) and anti-Epstein-Barr virus active agent. This represents a pharmaceutical chemistry application of L-arabinose as a chiral building block rather than a dietary supplement effect per se.

L-arabinose can also be used to synthesise L-ribose, an important pharmaceutical intermediate of anti-AIDS virus and anti-cancer drugs.

9. Body Systems and Health Areas Associated with L-Arabinose

Gastrointestinal / digestive system: Primary site of action (brush-border sucrase inhibition in the small intestinal mucosa); secondary effects via colonic fermentation and prebiotic activity.
Endocrine / metabolic system: Modulation of postprandial glucose, insulin, C-peptide, GLP-1, and GIP; potential effects on insulin resistance in metabolic syndrome (animal evidence).
Cardiovascular system: Indirect associations via effects on body weight, blood pressure, triglycerides, and cholesterol in animal and limited human metabolic syndrome studies.
Gut microbiome: Selective stimulation of beneficial species including Bifidobacterium, Gemmiger, and Blautia; promotion of SCFA production; possible alleviation of functional constipation.
Hepatic / fatty acid metabolism: In animal studies, alterations in expression of hepatic fatty acid oxidation genes (CPT-1α, PDK4, ACCα).

10. Dosage Forms and Doses Reported in Studies

The following doses are reported directly from published human and animal studies and should be understood in their study context:

1.3%, 2.7%, and 4% by weight of L-arabinose in sucrose beverages (75 g sucrose in 300 mL) were the doses tested in the Krog-Mikkelsen et al. (2011) randomised, double-blind, crossover human study. The 4% dose produced the most pronounced glycaemic effects.
7.5 g of L-arabinose co-ingested with 50 g of sucrose in a 200-mL drink was used in the Vreeken et al. (2022) double-blind, randomised crossover stable-isotope study in twelve healthy participants.
5 g of L-arabinose was added to drinks containing 50 g sucrose in water, with or without 22 g oil or 50 g starch, in the Pol et al. (2022) randomised cross-over trial in 23 healthy volunteers.
10% w/w L-arabinose in a 550 mL sucrose drink was used as a single acute treatment in a 2025 double-blind, randomised cross-over trial in 18 adults with impaired fasting glucose.
15% w/w L-arabinose was used as a supplement preceding a 2-day controlled sucrose-rich diet (9–10 en% sucrose) in the same 2025 trial.
In mouse studies, an ED₅₀ of 35 mg/kg body weight was determined for suppression of the increase in blood glucose after sucrose ingestion.
In a 30-day feeding study, groups with 3%, 5%, and 10% L-arabinose were tested for postprandial blood glucose and body weight effects.

No consensus dosing guidelines from governmental health bodies or official pharmacopoeial monographs were identified for L-arabinose as a dietary supplement at the time of this writing.

11. Safety Considerations and Interactions

11.1 Regulatory Safety Status

L-arabinose was approved as Generally Recognized as Safe (GRAS) by the U.S. FDA in 2018. The GRAS notice (GRN 000782) filed by Sensus America Inc. covered its use as a sweetener across a broad range of food categories at up to 15% by weight.

11.2 Caloric Value

L-arabinose has no caloric value, as it is not metabolized through normal carbohydrate pathways in animals and humans to a meaningful degree. It is not involved in metabolic processes in animals, thus L-arabinose is a non-caloric sugar.

11.3 Gastrointestinal Tolerability

In the key human crossover study, no effects on triacylglycerol, gastrointestinal symptoms, appetite ratings, or energy intake were observed at doses of up to 4% (by weight of sucrose) in beverage form. Possible digestive implications such as increased flatulence, diarrhoea, or stomach pain were not reported in available studies.

However, at higher doses or in the context of colonic fermentation, mild gastrointestinal effects are biologically plausible. Some side effects, such as stomachache and diarrhoea, are associated with the addition of L-arabinose.

11.4 Potential Interaction with Gut Microbiota and Infection Risk

A notable safety signal was identified in a 2024 preclinical study: non-caloric L-arabinose exacerbated infectious colitis by altering microbiota composition in an experimental model. Supplementation with L-arabinose has been shown to significantly improve glucose intolerance and gut microbiota incoordination in diabetes; however, since hyperglycaemia affects both microbiome structure and metabolism, a synergistic effect exerted by both L-arabinose and hyperglycaemia may further exacerbate colitis in certain contexts. This finding is preclinical and its relevance to human supplementation is not yet established, but it warrants attention in future research, particularly in individuals with inflammatory bowel conditions or impaired immunity.

11.5 Food Matrix and Efficacy Interactions

An important practical consideration is that the glycaemic efficacy of L-arabinose is dependent on the food matrix in which it is consumed. In healthy human participants, supplementation of 20% L-arabinose relative to carbohydrate content to a single solid mixed meal did not alter glycaemic or insulinaemic responses. The efficacy of applying L-arabinose appears to depend on the food matrix. This means that the presence of additional macronutrients, cooking processes, and other food components may attenuate its sucrase-inhibitory effect.

11.6 Interactions with Medications

No peer-reviewed human studies documenting pharmacokinetic drug interactions with L-arabinose were identified in the literature search. Because L-arabinose inhibits intestinal sucrase and may modulate gut microbiota, theoretical interactions with medications that depend on intestinal carbohydrate metabolism or that are affected by changes in gut flora are biologically plausible but unconfirmed in human data.

11.7 Populations with Special Considerations

There is a significant difference in study designs, mostly in terms of the investigated population (age, gender, and health status), administered dose and duration; there is an urgent need for additional, more well-designed clinical studies. Most existing human trials have been conducted in healthy adult populations. Data in pregnant women, children, elderly individuals with impaired renal or hepatic function, and individuals with sucrase-isomaltase deficiency are absent from the peer-reviewed literature.

12. Summary of Evidence Strength

Postprandial glycaemic and insulinaemic control (sucrose co-ingestion in beverages): Moderate evidence. Multiple randomised, double-blind crossover trials in humans consistently demonstrate acute benefit. Effect sizes are modest to moderate. Studies are typically small (12–23 participants), mostly acute, and often industry-associated. Findings are consistent but require confirmation in larger, long-term, independently funded trials.
Glycaemic effect in solid/mixed-meal contexts: Mixed/inconsistent evidence. Effects demonstrated in some studies and absent in others; food matrix appears to be a critical moderator.
Metabolic syndrome and body weight: Preliminary/weak human evidence; stronger animal evidence. One 6-month human observational-style study supports benefit, but methodological limitations are substantial. Rat studies are supportive but not directly translatable.
Prebiotic / gut microbiota effects: Preliminary. Mostly animal and in vitro data. Human gut microbiome studies are lacking.
Antiviral drug synthesis: Not a dietary supplement effect — a pharmaceutical chemistry application only.
Colitis / gastrointestinal inflammation: Preclinical only. Animal model data; contradictory signals in different models.

References

Health Conditions

Health conditions that Arabinose may help support.

No conditions available.

Body Systems

Body systems that Arabinose may help support.

No body systems available.